Maryland Medical Assistance Program - Step Therapy, Fail-First Protocols, and Prior Authorization - Prescription Drugs to Treat Serious Mental Illness
Summary
SB 490 would limit utilization management tools in the Maryland Medical Assistance Program for certain psychiatric medications. Beginning July 1, 2026, the program could not impose prior authorization or step therapy/fail-first requirements for prescription drugs used to treat an adult enrollee’s bipolar disorder, schizophrenia, major depression, post-traumatic stress disorder, or a medication-induced movement disorder associated with treatment of serious mental illness. The bill defines step therapy or fail-first protocol by reference to existing insurance law.
The bill is framed as a targeted access measure for Medicaid enrollees with serious mental illness. It applies only to the Maryland Medical Assistance Program and only to the listed diagnoses, and it preserves any prior authorization requirements that federal Medicaid law requires. The act is temporary: it takes effect July 1, 2026 and sunsets on June 30, 2029 unless extended by the General Assembly.
Impact
SB 490 would add a new section to the Health-General Article governing the Maryland Medical Assistance Program, restricting the program’s ability to use prior authorization and step therapy for specified mental health medications. In practice, this would reduce administrative barriers for affected adult Medicaid enrollees and could increase timely access to psychiatric treatment, while potentially affecting program cost controls and pharmacy utilization management policies. The bill would not broadly change private insurance law, but it incorporates an insurance-law definition of step therapy/fail-first protocols and creates a temporary Medicaid-specific exception to those controls.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of legislative debate or formal support/opposition in the available record. Based on the bill text alone, the measure appears to reflect a generally patient-access-oriented approach, prioritizing continuity and speed of treatment for serious mental illness. The temporary sunset suggests an intent to test the policy before deciding whether to make it permanent.
Contention
The likely point of contention is the tradeoff between access to psychiatric medications and the Maryland Medical Assistance Program’s ability to manage costs and encourage use of preferred drugs through prior authorization and step therapy. Supporters would likely emphasize reduced delays in treatment, fewer disruptions for patients with serious mental illness, and avoidance of harmful medication switching. Opponents or fiscal skeptics would likely focus on increased spending, reduced formulary management flexibility, and the possibility that removing utilization controls could lead to higher program costs. The bill’s exception for requirements mandated by federal Medicaid law also indicates an effort to avoid conflict with federal rules.